Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background: In 2013, the Thai Pediatric Oncology Group (ThaiPOG) introduced a national protocol in which highdose chemotherapy plus stem cell rescue is performed without immunotherapy. Methods: This study aimed to elucidate the outcomes of high-risk neuroblastoma (HR-NB) patients treated with the ThaiPOG protocol. This retrospective cohort review included 48 patients (30 males, 18 females) with a median age of 3 years (range, 8 months to 18 years) who were treated at 5 ThaiPOG treatment centers in Thailand in 2000–2018. Results: Eight of the 48 patients showed MYCN amplification. Twenty-three patients (48%) received131I-meta-iodobenzylguanidine prior to high-dose chemotherapy and stem cell rescue. The majority of patients achieved a complete or very good response prior to consolidation treatment. The 5-year overall survival (OS) and event-free survival (EFS) rates were 45.1% and 40.4%, respectively. Patients aged >2 years had a nonsignificantly higher mortality risk (hazard ratio [HR], 2.66; 95% confidence interval [CI], 0.92–7.68; P=0.07). The MYCN amplification group had lower OS and EFS rates than the MYCN nonamplification group, but the difference was not statistically significant (45% OS and 37.5% EFS vs. 33.3% OS and 16.6% EFS; P=0.67 and P=0.67, respectively). Cisretinoic acid treatment for 12 months was a strong prognostic factor that could reduce mortality rates among HR-NB patients (HR, 0.27; 95%CI, 0.09–0.785; P=0.01). Conclusion: High-dose chemotherapy plus stem cell rescue followed by cis-retinoic acid for 12 months was well tolerated and could improve the survival rates of patients with HR-NB.

References Powered by Scopus

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid

1686Citations
N/AReaders
Get full text

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

1464Citations
N/AReaders
Get full text

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study

743Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Suwannaying, K., Techavichit, P., Komvilaisak, P., Laoaroon, N., Narkbunnam, N., Sanpakit, K., … Wiangnon, S. (2022). Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand. Clinical and Experimental Pediatrics, 65(9), 453–458. https://doi.org/10.3345/cep.2022.00437

Readers over time

‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

50%

Environmental Science 1

50%

Save time finding and organizing research with Mendeley

Sign up for free
0